FDA Finally Addresses Interchangeable Biosimilars

Law360, New York (February 28, 2017, 11:54 AM EST) -- Christopher M. Mikson

Mark Mansour

Emily K. Strunk The U.S. Food and Drug Administration recently issued long-awaited draft guidance, "Considerations in Demonstrating Interchangeability With a Reference Product" (January 2017), addressing the standards for demonstrating interchangeability of biological products under the Biologics Price Competition and Innovation Act of 2009.

The BPCIA amended the Public Health Service Act to create an abbreviated pathway for FDA licensure of biologics that are biosimilar to, or interchangeable with, a reference product. Under the BPCIA, a product is biosimilar if it is highly similar to the reference product, notwithstanding minor differences in clinically inactive components and if...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!